Replimune Group Inc · Q4 2022 earnings

Briefing

Announced financial results for the fiscal fourth quarter and year ended March 31, 2022 and provided a business update.

Replimune reported their Q4 2022 financial results and corporate update, ending the fiscal year in a strong position. They are maintaining guidance to complete enrollment into the CERPASS clinical trial in CSCC mid-year and to release top line data in early 2023. Initial directional data from the IGNYTE clinical trial in anti-PD1 failed melanoma is expected in late 2022.

• Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) is expected to be completed in mid-year 2022; top line data expected Q1 2023.
• Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in anti-PD1 failed melanoma is expected in late 2022.
• Phase 2 development plan for RP2/RP3 in HCC, CRC and SCCHN announced.
• Existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.

Headline financials

Revenue & EPS history

Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.